10364-70-2 Usage
Uses
Used in Pharmaceutical Industry:
5-BUTYL-3-(4-NITROPHENYL)-1,2,4-OXADIAZOLE is used as a potential antitumor agent for its possible role in inhibiting the growth of cancer cells. Its specific structure may contribute to its activity against tumor development, making it a candidate for further research and development in oncology.
Used in Enzyme Inhibition:
In the field of biochemistry, 5-BUTYL-3-(4-NITROPHENYL)-1,2,4-OXADIAZOLE is utilized for its inhibitory effects on certain enzymes. This property can be significant in the development of drugs that target specific enzymatic pathways involved in disease processes.
Used in Organic Electronic Materials:
5-BUTYL-3-(4-NITROPHENYL)-1,2,4-OXADIAZOLE is also used in the synthesis of organic electronic materials. Its unique chemical structure may offer advantages in the performance of organic electronic devices, such as organic light-emitting diodes (OLEDs), organic photovoltaics (OPVs), and organic field-effect transistors (OFETs), where its properties could enhance device efficiency or stability.
Note: The uses listed are based on the information provided and the general knowledge of oxadiazole compounds. The specific applications and reasons may vary depending on the results of ongoing research and development in these fields.
Check Digit Verification of cas no
The CAS Registry Mumber 10364-70-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,0,3,6 and 4 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 10364-70:
(7*1)+(6*0)+(5*3)+(4*6)+(3*4)+(2*7)+(1*0)=72
72 % 10 = 2
So 10364-70-2 is a valid CAS Registry Number.
10364-70-2Relevant academic research and scientific papers
USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS
-
, (2017/10/30)
The present invention refers to compounds of formula I or II endowed with DDX3 inhibitory activity, relative pharmaceutical compositions and their use as antihyperproliferative agents. (I) or (II)
HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS
-
, (2016/09/22)
The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.
